Latest News

Samsung Bioepis receives FDA approval for Renflexis across all eligible indications

Samsung Bioepis receives FDA approval for Renflexis across all eligible indications

Paratek and Zai Lab sign deal to commercialise omadacycline in China

Paratek Pharmaceuticals has entered a collaboration with Chinese biopharmaceutical company Zai Lab (Shanghai) to support the development and commercialisation of omadacycline in...

Paratek and Zai Lab sign deal to commercialise omadacycline in China

Sanofi and Regeneron’s Kevzara receives CHMP opinion to treat Rheumatoid Arthritis

Regeneron Pharmaceuticals and Sanofi’s Kevzara (sarilumab) has received a positive opinion from the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) to...

Sanofi and Regeneron’s Kevzara receives CHMP opinion to treat Rheumatoid Arthritis

MPP signs licence and technology transfer agreement with Pharco Pharmaceuticals for RAV

MPP signs licence and technology transfer agreement with Pharco Pharmaceuticals for RAV

BioMarin’s Brineura receives positive opinion from CHMP to treat CLN2 disease

BioMarin’s Brineura receives positive opinion from CHMP to treat CLN2 disease

Valeant Pharmaceuticals lists price of plaque psoriasis drug at $3,500 per month

Valeant Pharmaceuticals International has decided to set the price of its biologic psoriasis treatment, known as Siliq (brodalumab) injection, at $3,500 per...

Valeant Pharmaceuticals lists price of plaque psoriasis drug at $3,500 per month

M&As this week: Livzon Pharmaceutical Group, PLx Pharma, Medis Laboratories

Chinese company Livzon Pharmaceutical Group has reached an agreement to sell its Pharma...

M&As this week: Livzon Pharmaceutical Group, PLx Pharma, Medis Laboratories

Novartis obtains rights to use Parvus’ Navacim to develop products for T1D

Novartis obtains rights to use Parvus’ Navacim to develop products for T1D

Deals this week: Grifols, Cellesce, Arena Pharmaceuticals

Spanish pharmaceutical company Grifols has raised €1bn ($1.06bn) through a public offering of...

Deals this week: Grifols, Cellesce, Arena Pharmaceuticals

Ionis and Ribo partner to commercialise RNA-targeted therapeutics in China

Ionis Pharmaceuticals has entered a collaboration and licence agreement with Suzhou Ribo Life Science (Ribo) to develop and commercialise ribonucleic acid (RNA)-targeted therapeutics in...

Ionis and Ribo partner to commercialise RNA-targeted therapeutics in China

GSK and Daiichi Sankyo JV submits NDA for candidate shingles vaccine in Japan

GSK and Daiichi Sankyo JV submits NDA for candidate shingles vaccine in Japan

HitGen and Pfizer partner to build and screen new DNA-Encoded Libraries

HitGen and Pfizer have entered a multi-year research collaboration and licence agreement to build and screen novel DNA-encoded libraries (DELs) to help discover unique small-molecule leads for...

HitGen and Pfizer partner to build and screen new DNA-Encoded Libraries

PLx Pharma merges with Dipexium Pharmaceuticals

Late-stage specialty pharmaceutical company PLx Pharma has completed its previously announced merger with Dipexium...

PLx Pharma merges with Dipexium Pharmaceuticals

Rigel Pharmaceuticals submits NDA to FDA for Fostamatinib to treat chronic ITP

Rigel Pharmaceuticals has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for an oral investigational drug candidate, Fostamatinib, for the treatment of ...

Rigel Pharmaceuticals submits NDA to FDA for Fostamatinib to treat chronic ITP

Cancer Research UK, CPF and NCI partner to develop tests to analyse RAS inhibitors

Cancer Research UK, CPF and NCI partner to develop tests to analyse RAS inhibitors

FDA grants Breakthrough Therapy designation to Novartis CTL019 for DLBCL

FDA grants Breakthrough Therapy designation to Novartis CTL019 for DLBCL

US FDA declines approval of Eli Lilly and Incyte’s baricitinib drug to treat RA

Eli Lilly and partner Incyte have announced that the US Food and Drug Administration (FDA) has declined to approve a new drug, baricitinib, to treat moderate-to-severe rheumatoid arthritis...

US FDA declines approval of Eli Lilly and Incyte’s baricitinib drug to treat RA

Alk’s HDM tablet Acarizax secures approval for expansion in 12 European countries

Alk’s HDM tablet Acarizax secures approval for expansion in 12 European countries

Genentech's Tecentriq receives FDA-accelerated approval for advanced bladder cancer treatment

Roche Group member Genentech has received accelerated approval from the US Food and Drug Administration (FDA) for Tecentriq (atezolizumab) to treat patients with locally advanced or...

Genentech's Tecentriq receives FDA-accelerated approval for advanced bladder cancer treatment

Deals this week: Frequency Therapeutics, Emerald Health Therapeutics, Immune System Regulation Holding

US-based small-molecule drug provider Frequency Therapeutics has completed a series A financing round to raise $32m in order to support expanded work to realise the disease-modifying potential...

Deals this week: Frequency Therapeutics, Emerald Health Therapeutics, Immune System Regulation Holding

US FDA approves Neurocrine’s Ingrezza capsules to treat tardive dyskinesia

US FDA approves Neurocrine’s Ingrezza capsules to treat tardive dyskinesia